Halma (LSE:HLMA), the FTSE 100 life-safety technology group, has acquired itemedical and Naslund Medical for a combined consideration of approximately £54m, adding digital hospital workflow capabilities and precision radiation oncology technology to its healthcare portfolio.
itemedical, a Dutch provider of digital platforms that integrates real-time patient data and device alarms to support clinical decision-making, was acquired for €23m (approximately £20m) in cash from existing facilities.
The business had unaudited revenue of €7.8m (approximately £7m) for the 12 months to 31 March, implying an acquisition multiple of roughly 2.9 times revenue.
itemedical will be integrated into Halma subsidiary SSG, expanding its hospital workflow management offering.
Naslund Medical, a Swedish specialist in fiducial marker technology for targeted cancer treatment, was acquired for $45m (approximately £34m) in cash, also from existing facilities.
Its core product, Gold Anchor, supports tumour targeting during radiation therapy and will be added to the portfolio of IZI Medical, Halma's existing radiation oncology business.
Naslund generated unaudited revenue of $9.2m (approximately £7m) in the same period, implying a revenue multiple of roughly 4.9 times.
Group chief executive Marc Ronchetti said the acquisitions "strengthen our existing companies by adding complementary capabilities in markets they know well, supporting their long-term growth while enabling improved patient outcomes."
Both deals completed on a cash- and debt-free basis with no shareholder approval required.
